Source: Aastrom Biosciences, Inc.
Date: January 17, 2007
Summary:
Aastrom Biosciences, Inc. (Nasdaq: ASTM), a company focused on the use of adult stem cells for regenerative medicine, today announced that the first two patients have been treated in a pivotal clinical trial utilizing the Company's Tissue Repair Cells (TRCs) for the treatment of osteonecrosis, or degeneration, of the femur.
No comments:
Post a Comment